Michael J. Birrer

Oncology
619 19th St S
Birmingham, AL 35249

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 197 publications

TGF-β Is Critical for Ovarian Cancer Migration, Invasion, and Chemosensitivity.

TGF-β Is Critical for Ovarian Cancer Migration, Invasion, and Chemosensitivity.

Journal: Cancers
Published: April 10, 2026

Quality-of-life outcomes in newly diagnosed advanced cancer: subgroup analysis - a case for individual differences.

Quality-of-life outcomes in newly diagnosed advanced cancer: subgroup analysis - a case for individual differences.

Journal: BMJ supportive & palliative care
Published: December 19, 2025

An alternative perspective on the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being 12 item Scale (FACIT-Sp-12) in people newly diagnosed with advanced cancer.

An alternative perspective on the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being 12 item Scale (FACIT-Sp-12) in people newly diagnosed with advanced cancer.

Journal: Journal of psychosocial oncology
Published: November 19, 2025

Detection of mutant cancer-derived circRNAs in extracellular vesicles by rolling circle amplification.

Detection of mutant cancer-derived circRNAs in extracellular vesicles by rolling circle amplification.

Journal: Molecular therapy. Nucleic acids
Published: August 05, 2025

Exploring survival-associated transcriptomic subtypes in ovarian cancer using RNAseq from FFPE tissues in a clinical trial cohort.

Exploring survival-associated transcriptomic subtypes in ovarian cancer using RNAseq from FFPE tissues in a clinical trial cohort.

Journal: Translational oncology
Published: May 24, 2025

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.

Journal: Gynecologic oncology
Published: April 05, 2025

Questions and answers on PARP inhibitor use in somatic BRCA-mutated breast cancers.

Questions and answers on PARP inhibitor use in somatic BRCA-mutated breast cancers.

Journal: Journal of the National Cancer Institute
Published: March 12, 2025

Self-affirmation intervention for patients newly diagnosed with advanced cancer: a preliminary efficacy trial.

Self-affirmation intervention for patients newly diagnosed with advanced cancer: a preliminary efficacy trial.

Journal: Journal of psychosocial oncology
Published: January 15, 2025

Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial.

Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial.

Journal: JAMA oncology
Published: July 25, 2024

Single-cell analysis of ovarian myeloid cells identifies age-associated changes in macrophages and signaling dynamics†.

Single-cell analysis of ovarian myeloid cells identifies age-associated changes in macrophages and signaling dynamics†.

Journal: Biology of reproduction
Published: July 08, 2024

Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.

Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.

Journal: Gynecologic oncology
Published: July 01, 2024

Single-cell analysis of ovarian myeloid cells identifies aging associated changes in macrophages and signaling dynamics.

Single-cell analysis of ovarian myeloid cells identifies aging associated changes in macrophages and signaling dynamics.

Journal: bioRxiv : the preprint server for biology
Published: June 25, 2024
Showing 1-12 of 197

Last Updated: 09/26/2026